Recently, several models of ChoiceMMed oxygen concentrators have successfully obtained certification under the European Union's new Medical Device Regulation(CE-MDR). This achievement marks a critical passport for ChoiceMMed oxygen concentrators to enter the EU market and once again validates that ChoiceMMed's technical standards and quality management system align with high international benchmarks.

ChoiceMMed consistently places paramount importance on product safety and patient benefits. To this end, the company has proactively established a global market access framework, actively securing international authoritative certifications including those from the US FDA and the EU CE. This ensures that its innovative outcomes can safely and reliably benefit a broader global user base. 

Driven by core technological R&D, ChoiceMMed is committed to providing world-class, intelligent, and wearable medical health management products and services to global healthcare institutions and families. The company has built a comprehensive product matrix covering three core areas:blood oxygen monitoring,respiratory care, and cardiovascular health. Within this portfolio, multiple models in its pulse oximeters series have gained international authoritative recognition, including US FDA 510(k) clearance. The successful acquisition of the EU CE-MDR certification for its oxygen concentrators represents another milestone in deepening the operation of ChoiceMMed's respiratory product line within mainstream global markets. ChoiceMMed will continue to intensify R&D efforts,steadfastly uphold quality benchmarks, and expand its global presence, delivering innovative and intelligent health technology products and services to more households worldwide.